

# THERAPy de-escalation for TESTicular cancer

<b>Submission date</b> 22/02/2024	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 12/08/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

THERATEST is looking to collect data from patients with testicular cancer actively receiving de-escalation treatments or other standard-of-care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether a larger study should proceed with these treatments, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study, improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. THERATEST aims to bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.

### Who can participate?

Patients with testicular cancer aged from 16 to 100 years old

### What does the study involve?

Eligible participants will receive one of two possible treatment strategies:

De-escalation treatment with Carboplatin AUC 10 at 21-day intervals. Each 21-day interval is called a cycle. Carboplatin is administered by injecting it into a vein through a cannula over approximately 60 minutes in a hospital. Three cycles of this treatment will be given.

OR

Other types of standard-of-care treatments such as combination chemotherapy (e.g. bleomycin, etoposide and platinum (BEP) or etoposide and platinum (EP)) or radiotherapy. These will be offered to participants if they do not wish to receive Carboplatin AUC10 or if their doctor believes this is not the best treatment option for them. The details of the duration and frequency of these treatments will be given to them by your doctor.

After completing the treatment, participants will be followed for 2 years. This will allow the collection of data on long-term side effects, how well the treatment controlled the growth of the cancer as well as the impact it had on quality of life. All visits will be in line with standard-of-care visits and they will not have to attend additional hospital visits.

What are the possible benefits and risks of participating?

This trial aims to find out information that may help people with testicular cancer. The treatments participants will receive are the same as standard-of-care treatments. There is no additional benefit over and above the standard of care.

Where is the study run from?

Queen Mary University of London (Queen Mary) is the Sponsor for this study and it is based in the United Kingdom.

When is the study starting and how long is it expected to run for?

May 2023 to May 2028

Who is funding the study?

Barts Charity

Who is the main contact?

bci-theratest@qmul.ac.uk

## Contact information

### Type(s)

Public, Scientific, Principal Investigator

### Contact name

Mr Prabhakar Rajan

### Contact details

Queen Mary University of London, Charterhouse Square  
London

United Kingdom

EC1M 6BQ

020 7882 8487

bci-theratest@qmul.ac.uk

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

305109

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

IRAS 305109, CPMS 59883

## Study information

**Scientific Title**

THERApy de-escalation for TESTicular cancer

**Acronym**

THERATEST

**Study objectives**

THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether a larger study should proceed with these treatments, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study, improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. It is hoped that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

Approved 24/01/2024, REC London Riverside (2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8243; riverside.rec@hra.nhs.uk), ref: 23/LO/0972

**Study design**

Observational cohort study

**Primary study design**

Observational

**Secondary study design**

Cohort study

**Study setting(s)**

Hospice

**Study type(s)**

Other, Quality of life

**Participant information sheet**

Not available in web format

**Health condition(s) or problem(s) studied**

Patients with testicular seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3 cm IIB will be assessed for robot-assisted retroperitoneal lymph node dissection (rRPLND)

**Interventions**

THERATEST is an observational cohort study of patients receiving standard-of-care (SOC) treatments (combination chemotherapy or radiotherapy) or de-escalated treatments (primary rRPLND or Carboplatin AUC10) for stage II seminoma.

A. rRPLND cohort: Patients with seminoma who are negative/low for tumour markers and unifocal ipsilateral Stage IIA or <3cm IIB will be assessed for rRPLND. Patients who are eligible for rRPLND will undergo surgery followed by adjuvant treatment or surveillance as determined by their clinical teams based on post-operative histology as per SOC. Patients who are not deemed eligible for or decline rRPLND will be offered either BEP/EP chemotherapy or radiotherapy with or without neoadjuvant Carboplatin AUC7 and will continue to be followed in the study.

B. Carboplatin AUC10 cohort: Patients with stage II seminoma will be offered Carboplatin AUC10. Those deemed ineligible for Carboplatin AUC10 or who decline this treatment option will be offered either BEP/EP chemotherapy or radiotherapy and will continue to be followed in the study.

## **Intervention Type**

Procedure/Surgery

## **Primary outcome measure**

Feasibility will be measured using recruitment and retention (number of participants recruited per month and retained annually) data collected from the patient visits and recorded within the study electronic database at one time point

## **Secondary outcome measures**

1. Health-related quality of life measured using the change in domain scale scores/single item scores in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-TC26 and EORTC QLQ-C30 before and after treatment(s)
2. Sexual drive, function, and overall satisfaction measured using the change in domain scale scores/single item scores in Brief Male Sexual Function Inventory (BMSFI), QLQ-TC26, and supplementary questions on retrograde ejaculation before and after treatment(s)
3. Progression-free survival (PFS) and overall survival (OS) rates to ensure these fall in line with standard-of-care treatment outcomes (>95%) [PFS rate at 2 years, defined as the proportion of patients who did not experience disease progression or death from any cause during the 2-year follow-up period. OS rate at 2 years, defined as the proportion of patients who did not experience death from any cause during the 2-year follow-up period.]
4. Safety and complications of all treatments measured using the incidence, nature and severity of adverse events with severity determined according to CTCAE v5.0 collected from consent until 6 weeks post-surgery or chemotherapy. Surgical complications will be assessed by the Clavien-Dindo scoring system, and analysing details of surgical complications, blood transfusion, ITU admission and dialysis rates from patient records up to 6 months post-rRPLND.

## **Overall study start date**

30/05/2023

## **Completion date**

31/05/2028

# **Eligibility**

## **Key inclusion criteria**

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

1. Willing and able to provide written informed consent
2. Male

3. Age  $\geq 16$  years
4. Histologically confirmed seminoma (biopsy/orchidectomy)
5. Clinical stage II (standard of care cross-sectional imaging)
6. Ability to comply with the protocol, including but not limited to, completion of the patient-reported outcome questionnaires. rRPLND cohort-specific inclusion criteria

Participants must meet the following additional inclusion criteria to register for the rRPLND cohort:

1. Stage IIA and  $< 3$  cm IIB with unifocal ipsilateral lymph node within rRPLND template.
2. Negative or mildly elevated serum tumour markers, defined as:
  - 2.1. AFP (alpha-fetoprotein)  $< 10$  ng/ml and non-rising on serial testing
  - 2.2. BhCG (human chorionic gonadotropin)  $< 50$  mg/ml
  - 2.3. LDH (lactate dehydrogenase)  $< 1.5$ x upper limit normal
3. Fit for surgery, defined as meeting all of the following criteria:
  - 3.1. Body mass index (BMI)  $< 34$
  - 3.2. Charlson comorbidity index  $\leq 3$
  - 3.3. ECOG Performance status 0-1
  - 3.4. No significant cardio-pulmonary disease, or other uncontrolled intercurrent illness that would limit fitness for surgery in the opinion of the investigator
  - 3.5. No previous open intra-abdominal surgery Carboplatin AUC10 cohort-specific inclusion criteria

Participants must meet the following additional inclusion criteria to register for the Carboplatin AUC10 group:

1. Serum tumour markers, defined by IGCCCG "good risk" criteria:
  - 1.1. AFP  $< 10$  ng/ml
  - 1.2. any BhCG
  - 1.3. LDH  $< 2.5$ x ULN
2. Glomerular filtration rate by EDTA clearance over 25 ml/min (a measured creatinine clearance using Cockcroft and Gault would be allowed if unable to perform EDTA clearance)
3. ECOG Performance status 0-2
4. Patients must be sterile or agree to use adequate contraception during the period of therapy

### **Participant type(s)**

Patient

### **Age group**

Mixed

### **Lower age limit**

16 Years

### **Upper age limit**

100 Years

### **Sex**

Male

### **Target number of participants**

30

## Key exclusion criteria

A patient will not be eligible for inclusion in this study if any of the following criteria apply:

1. Raised AFP > 10ng/ml that does not fall to <10ng/ml following orchidectomy
2. Previous chemotherapy or radiotherapy for the disease under study.
3. Previous or concurrent malignancy other than testicular cancer, unless treated with curative intent and with no known active disease present for  $\geq 2$  years before enrolment and felt to be at low risk for recurrence by the treating physician (for example: non-melanoma skin cancer or lentigo maligna; breast ductal carcinoma in situ; prostatic intraepithelial neoplasia; urothelial papillary non-invasive carcinoma or urothelial carcinoma in situ).
4. Any condition that, in the opinion of the investigator, would interfere with the evaluation of study intervention or interpretation of patient safety or study results such as medical comorbidities impacting on QoL or medical conditions or other disorders that would affect adherence to study requirements.

## Date of first enrolment

12/08/2024

## Date of final enrolment

28/02/2026

## Locations

### Countries of recruitment

England

United Kingdom

### Study participating centre

#### Barts Health NHS Trust

The Royal London Hospital

80 Newark Street

London

United Kingdom

E1 2ES

### Study participating centre

#### Royal Marsden Hospital

Royal Marsden Hospital

Downs Road

Sutton

United Kingdom

SM2 5PT

## Sponsor information

**Organisation**

Queen Mary University of London

**Sponsor details**

Joint Research Management Office, Research Services Dept. W, 69-89 Mile End Rd  
London  
England  
United Kingdom  
E1 4UJ  
+44 (0)20 7882 8002  
research.governance@qmul.ac.uk

**Sponsor type**

University/education

**Website**

<https://www.qmul.ac.uk/>

**ROR**

<https://ror.org/026zzn846>

**Funder(s)****Funder type**

Charity

**Funder Name**

Barts Charity

**Alternative Name(s)****Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United Kingdom

**Results and Publications**

Publication and dissemination plan

This is an investigator-led study sponsored by the CI’s substantive employer, Queen Mary University of London. Authorship of the final manuscript(s), interim publications, or abstracts will be decided according to active participation in the statistical design, TMG, accrual of eligible patients and statistical analysis. Contributing centres and participating investigators will be acknowledged in the final manuscript. All publications will acknowledge the sponsor. The correct designation for the sponsor is Queen Mary University of London. No participant or investigator may present data from his/her centre separately from the rest of the study results unless approved by the TMG and the sponsor. The sponsor will be notified of any planned outputs of the research such as guidelines, publications, presentation, changes in service delivery etc. prior to external submission or presentation. All publications will be sent to the JRMO prior to publication. The full study report will be accessible via the HRA website or other suitable public website within one year of the End of the Trial Notification.

**Intention to publish date**

31/12/2027

**Individual participant data (IPD) sharing plan**

All study data shall be the property of Queen Mary University of London.  
THERATEST Protocol v2.0 12 Dec 2023 Page 48 of 50

In the event that research misconduct or data integrity concerns have been raised, the sponsor, with senior management of the affected organisation in discussion with the CI, reserves the right to review, request a hold on publication submission or to refuse permission to publish. Responsibility for ensuring the accuracy of any publication from this study is delegated to the CI.

**IPD sharing plan summary**

Data sharing statement to be made available at a later date

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		29/07/2025	04/08/2025	Yes	No